We next examined and compared the expression of HNRNPA2B1 in matched cancer and paraneoplastic tissue samples from our hospital, and higher expression levels of HNRNPA2B1 were also observed in tumor tissues from ESCA, STAD, COAD, READ, LIHC, LUSC, BRCA, CESC, LGG, BLCA, DLBC, HNSC, GBM, PRAD, and PAAD patients, and lower expression levels of HNRNPA2B1 were observed in tumor tissues from KIRC patients (Supplementary figure 1). This evidence concerns the gene HNRNPA2B1 and prostate adenocarcinoma.